Skip to main content
SpringerLink
Log in

Discovery and Design of Inhibitors of Oncogenic Tyrosine Kinases

  • Conference paper
New Approaches in Cancer Pharmacology: Drug Design and Development

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The recognition that we may be approaching a plateau of effectiveness with traditional anticancer agents has led to the view that to gain more than incremental value against the major solid tumours will require a radically different strategy. Rather than the “black box” approach of random screening for cytotoxicity or cytostasis, or even the rational design of improved agents acting on conventional drug targets [1,2], many believe that this quantum leap will come from an exploitation of the identification of the genes and their encoded protein products which control proliferation, differentiation and cell death, combined with an understanding of their aberrant behaviour in malignant cells. Cancer is now described in extraordinary detail at the molecular level as a genetic disease. As a result of the remarkable advances in molecular oncology made over the last few years, the new central dogma of cancer drug discovery can be defined as: new biology → new targets → new therapies [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Johnson RK: Screening methods in drug discovery. JNCI 1990 (82):1082–1083

    PubMed  CAS  Google Scholar 

  2. Schwartsmann G and Workman P: Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer 1993 (29A):3–14

    Article  Google Scholar 

  3. Workman P (ed) New anticancer drug design based on advances in molecular oncology. Sem Cancer Biol 1992 (3):329–333

    Google Scholar 

  4. Vogelstein B and Kinzler KW: The multistep nature of cancer. Trends Genetics 1993 (9):138–141

    Article  CAS  Google Scholar 

  5. Powis G: Signalling targets for anticancer drug development. Trends Pharm Sci 1991 (12):188–193

    Article  PubMed  CAS  Google Scholar 

  6. Brunton VG and Workman P: Cell-signalling targets for antitumour drug development. Cancer Chemother Pharmacol 1993 (32):1–19

    Article  PubMed  CAS  Google Scholar 

  7. Kenyon GL and Garcia GA: Design of kinase inhibitors. Med Res Rev 1987 (7):389–416

    Article  PubMed  CAS  Google Scholar 

  8. Levitski A: Tyrphostins — potential antiproliferative agents and novel molecular tools. Biochem Pharmac 1990 (40):313–318

    Google Scholar 

  9. Chang C-J and Geahlen RL: Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Natural Products 1992 (11):1529–1560

    Article  Google Scholar 

  10. Workman P, Brunton VG, Robins DJ: Tyrosine kinase inhibitors. Sem Cancer Biol 1992 (3):369–381

    CAS  Google Scholar 

  11. Burke TR: Protein-tyrosine kinase inhibitors. Drugs of the Future 1992 (17):119–131

    Google Scholar 

  12. Spence P: Inhibitors of tyrosine kinase activity as anticancer therapeutics: recent developments. Current Opinion in Therapeutic Patents, December 1992

    Google Scholar 

  13. Dobrusin EM and Fry DW: Protein tyrosine kinases and cancer. Ann Rep Med Chem 1992 (27):169–176

    Article  CAS  Google Scholar 

  14. Hunter T: A thousand and one protein kinases. Cell 1987(50):823–829

    Article  PubMed  CAS  Google Scholar 

  15. Gescher A: Towards selective pharmacological modulation of protein kinase C — opportunities for the development of novel antineoplastic agents. Br J Cancer 1992 (66):10–19

    Article  PubMed  CAS  Google Scholar 

  16. Grunicke HH and Uberall F: Protein kinase C modulation. Sem Cancer Biology 1992 (3):351–360

    CAS  Google Scholar 

  17. Fantl W, Johnson DE, Williams RT: Signalling by receptor tyrosine kinases. Ann Rev Biochem 1993 (62):453–481

    Article  PubMed  CAS  Google Scholar 

  18. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 (235):177–181

    Article  PubMed  CAS  Google Scholar 

  19. Slamon DJ, Godolphin W, Jones LA et al: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 (244):707–712

    Article  PubMed  CAS  Google Scholar 

  20. Bicknell R and Harris AL: Anticancer strategies involving vasculature: vascular targeting and the inhibition of angiogenesis. Sem Cancer Biology 1992(3):399–407

    CAS  Google Scholar 

  21. Bolen JB, Veillette A, Schwartz A, DeSeau V, Rosen N: Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci 1987 (84) :2251–2255

    Article  PubMed  CAS  Google Scholar 

  22. Ottenhoff-Kalff AE, Rijksen G, van Bearden EACM, Hennipman A, Michels AA, Staal GEJ: Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 1992 (52):4773–4778

    Google Scholar 

  23. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985 (315):550–554

    Article  PubMed  CAS  Google Scholar 

  24. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990 (61):203–213

    Article  PubMed  CAS  Google Scholar 

  25. Snyder MA, Bishop JM, McGrath JP, Levinson AD: A mutation at the ATP-binding site of pp60c-src abolishes kinase activity, transformation, and tumorigenicity. Mol Cell Biol 1985 (5):1772–1779

    PubMed  CAS  Google Scholar 

  26. Stein PL, Imamoto A, Soriano P: Genetic analysis of src-family tyrosine kinase mouse mutants. Proc Am Assoc Cancer Res 1993 (34):575

    Google Scholar 

  27. Hanks SK, Quinn AM, Hunter T: The protein kinase family: conserved features and deduced phytogeny of the catalytic domains. Science 1988 (241):42–52

    Article  PubMed  CAS  Google Scholar 

  28. Knighton DR, Zheng J, Ten Eyck LF, Ashford VA, Xuong N-H, Taylor SS, Sowadski JM: Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991 (253):407–414

    Article  PubMed  CAS  Google Scholar 

  29. Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Xuong N-H, Taylor S, Sowadski JM: Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993 (32):2154–2161

    Article  PubMed  CAS  Google Scholar 

  30. Bossemeyer D, Engh RA, Kinzel V, Ponstinyl H, Huber R: Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn2+ adenyl imidophosphate and inhibitor peptide PKI (5–24). EMBO J 1993 (3):849–859

    Google Scholar 

  31. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim S-H: Crystal structure of cyclin-dependent kinase 2. Science 1993 (363):595–603

    Google Scholar 

  32. Knighton DR, Cadena DL, Zheng J, Ten Eyck LF, Taylor SS, Sowadski JM, Gill GN: Structural features that specify tyrosine kinase activity deduced from homology modelling of the epidermal growth factor receptor. Proc Natl Acad Sci 1993 (90):5001–5005

    Article  PubMed  CAS  Google Scholar 

  33. Robinson S, Dean BJ, Petty BA: Characterization of A431 tumor xenograft as an in vivo model for testing epidermal growth factor-receptor antagonists. Int J Oncol 1992 (1):293–298

    PubMed  CAS  Google Scholar 

  34. Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H: Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/ threonine protein kinases. Biochem Pharmac 1988 (37):2987–2992

    Article  CAS  Google Scholar 

  35. Okura A, Arakawa H, Oka H, Yoshinari T, Moden Y: Effect of genistein on topoisomerase activity and on the growth of Ha-ras-transformed NIH3T3 cells. Biochem Biophys Res Comm 1988 (157):183–189

    Article  PubMed  CAS  Google Scholar 

  36. Cushman M, Nagarathnam D, Burg DL, Geahlen RL: Synthesis and protein tyrosine kinase inhibitory activities of flavonoid analogues. J Med Chem 1991 (34):798–806

    Article  PubMed  CAS  Google Scholar 

  37. Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA: Alteration of a p34cdc2 kinase by the flavone L86–8275 in breast carcinoma cells. Biochem Pharmac 1993 (46):1831–1840

    Article  CAS  Google Scholar 

  38. Geahlen RL and McLaughlin JL: Piceatannol (3,4,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Comm 1989 (165):241–245

    Article  PubMed  CAS  Google Scholar 

  39. Cunningham BDM, Threadgill MD, Groundwater PW, Dale IL, Hickman JA: Synthesis and biological evaluation of protein tyrosine kinases. Anti-Cancer Drug Design 1992 (7):365–384

    PubMed  CAS  Google Scholar 

  40. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada H, Hamada M, Takeuchi T: Studies on a new epidermal growth factor receptor kinase inhibitor, erbstatin, produced by MH 435-hF3. J Antibiot 1986 (39):170–173

    PubMed  CAS  Google Scholar 

  41. Yaish P, Gazit A, Gilon C, Levitski A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988 (242):933–935

    Article  PubMed  CAS  Google Scholar 

  42. Gazit A, Osherov N, Posner I, Yaish P, Pradosy E, Gilon C, Levitski A: Tyrphostins 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyrosine kinases. J Med Chem 1991 (34):1897–1907

    Article  Google Scholar 

  43. Brunton VG, Lear MJ, Robins DJ, Williamson S, Workman P: Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties. Anti-Cancer Drug Design 1994 (in press)

    Google Scholar 

  44. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitski A, Zilbertstein A, Mundy GR: The antiproliferative effects of tyrosine kinase inhibitors tyrphostins and a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 1991 (51):4430–4435

    PubMed  CAS  Google Scholar 

  45. Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K: Specific inhibitors of tyrosine specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Comm 1987 (147):322–328

    Article  PubMed  CAS  Google Scholar 

  46. Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, Lydon N: Sulfonylbenzoylnitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine kinase. J Med Chem 1991 (34):2328–2337

    Article  PubMed  CAS  Google Scholar 

  47. Geissler JF, Traxler P, Regenass U, Murray BJ, Roessel JL, Meyer T, McGlynn E, Storni A, Lydon NB: Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J Biol Chem 1990 (265):22255–22261

    PubMed  CAS  Google Scholar 

  48. Traxler P, Buchdunger E, Mett H, Meyer T, Regenass U, Roesel J, Trinks U, Lydon N: Amino-alkyl-acrylophenones as potent and selective inhibitors of the EGF-receptor protein tyrosine kinase. Proc Am Assoc Cancer Res 1992 (33):527

    Google Scholar 

  49. Kraker AJ, Wemple, Schemmel ME, Moore CW: Inhibition of epidermal growth factor receptor tyrosine kinase by 2-thioindoles, a new structural class of tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 1993 (34):408

    Google Scholar 

  50. Lydon N, Buchdunger E, Mett H, Regenass U, Muller M, Trinks U, Traxler P: Biological profile of CGP 52411: a tyrosine protein kinase inhibitor with selectivity for the EGF-receptor enzyme family. J Cell Biochem Suppl 1993 (17A):235

    Google Scholar 

  51. Buchdunger F et al: 4,5-dianilino-phthalimide: a novel tyrosine protein kinase inhibitor with selectivity for the EGF receptor signal transduction pathway and potent in vivo antitumour activity. Proc Natl Acad Sci 1994 (in press)

    Google Scholar 

  52. Uchara Y, Hori M, Takeuchi T, Umezawa H: Screening of agents which convert ‘transformed morphology’: identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 1985 (76):672–675

    Google Scholar 

  53. Uchara Y, Fukazawa H, Murakami Y, Mizuno S: Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulphydryl compounds. Biochem Biophys Res Comm 1989 (163):803–809

    Article  Google Scholar 

  54. Hamaguchi M, Xiao H, Uchara Y, Ohnishi Y, Nagai Y: Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phospha-tidylinositol 3′kinase. Oncogene 1993 (8):559–564

    PubMed  CAS  Google Scholar 

  55. Pelech L: Networking with protein kinases. Current Biology 1993 (3):513–515

    Article  PubMed  CAS  Google Scholar 

  56. Moodie SA and Wolfman A: The 3 Rs of life: Ras, raf and growth regulation. Trends Genetics 1994 (10):44–48

    Article  CAS  Google Scholar 

  57. Pawson T and Schlessinger J: SH2 and SH3 domains. Current Biology 1993 (3):434–442

    Article  PubMed  CAS  Google Scholar 

  58. Songyang Z, Schoelson SE, Chaudhuri M et al: SH2 domains recognize specific phosphopeptide sequences. Cell 1983 (72):767–778

    Google Scholar 

  59. McNamara DJ, Dobrusin E, Zhu G, Decker SJ, Saltiel AR: Inhibition of the binding of phospholipase Cγ1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides. Int J Peptide Protein Res 1993 (42):240–248

    Article  CAS  Google Scholar 

  60. McCormick F: How receptors turn ras on. Nature 1993(363):15–16

    Article  PubMed  CAS  Google Scholar 

  61. Wu J, Dent P, Jelinek T, Wolfman A, Weber M, Sturgill TW: Inhibition of the EGF-activated MAP kinase signalling pathway by adenosine 3′,5′-mono-phosphate. Science 1993 (262):1065–1069

    Article  PubMed  CAS  Google Scholar 

  62. Cook SJ and McCormick F: Inhibition by cAMP of ras-dependent activation of raf. Science 1993 (262):1069–1072

    Article  PubMed  CAS  Google Scholar 

  63. Graves LM, Bomfeldt KE, Raines EW, Potts BC, MacDonald SG, Ross R, Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signalling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 1993 (90):10300–10304

    Article  PubMed  CAS  Google Scholar 

  64. Silvennoinen O, Schindler C, Schlessinger J, Levy DE: Ras-independent growth factor signalling by transcription factor tyrosine phosphorylation. Science 1993 (261):1736–1739

    Article  PubMed  CAS  Google Scholar 

  65. Sadowski HB, Shuai K, Darnell JE, Gilman MZ: A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993 (261):1739–1743

    Article  PubMed  CAS  Google Scholar 

  66. Fu X-Y and Zhang J-J: Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 1993 (74):1135–1145

    Article  PubMed  CAS  Google Scholar 

  67. Bos JL: Ras oncogenes and human cancer: A review. Cancer Res 1989 (49):4682–4689

    PubMed  CAS  Google Scholar 

  68. James GL, Goldstein JL, Brown MS et al: Benzodiazepine peptidomimetics: Potent inhibitors of ras famesylation in animal cells. Science 1993 (260):1937–1942

    Article  PubMed  CAS  Google Scholar 

  69. Kohl NE, Mosser SD, de Solms J, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras- dependent transformation by a farnesyltransferase inhibitor. Science 1993 (260):1934–1937

    Article  PubMed  CAS  Google Scholar 

  70. Waksman G, Kominos D, Robertson SC et al: Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 1992 (358):646–653

    Article  PubMed  CAS  Google Scholar 

  71. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972 (26):239–157

    Article  PubMed  CAS  Google Scholar 

  72. Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 1980 (68): 251–300

    Article  PubMed  CAS  Google Scholar 

  73. Dive C, Evans CE, Whetton AD: Induction of apoptosis — new targets for cancer chemotherapy. Sem Cancer Biology 1992 (3):417–427

    CAS  Google Scholar 

  74. Raff M: Social controls on cell survival and death. Nature 1992 (356):397–400

    Article  PubMed  CAS  Google Scholar 

  75. Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 oncogene. Nature 1992 (359):554–556

    Article  PubMed  CAS  Google Scholar 

  76. Workman P and Graham MA: Pharmacokinetics of Cancer Chemotherapy. Cancer Surveys, Vol 17. Cold Spring Harbor, 1993

    Google Scholar 

  77. Zachary I and Rozengurt E: Focal adhesion kinase (p125FAK): A point of convergence in the action of neuropeptides, integrins and oncogenes. Cell 1992 (71):891–894

    Article  PubMed  CAS  Google Scholar 

  78. Weiner TM, Liu EJ, Craven RJ Cance WG: Expression of focal adhesion kinase gene and invasive cancer. Lancet 1993 (342):1024–1025

    Article  PubMed  CAS  Google Scholar 

  79. Millauer B, Shawver LK, Plate KH, Risan W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 1994 (367):576–579

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Campaign Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK

    Paul Workman & Valerie G. Brunton

  2. Department of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK

    David J. Robins

Authors
  1. Paul Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valerie G. Brunton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Robins
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research Campaign Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, UK

    Paul Workman (Chairman) (Chairman)

  2. Istituto Mario Negri, Via Eritrea 62, 20157, Milano, Italy

    Maurizio D’lncalci (Co-Chairman) (Co-Chairman)

  3. Cancer Research Department, ZENECA Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    Paul Workman (Chairman) (Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Workman, P., Brunton, V.G., Robins, D.J. (1994). Discovery and Design of Inhibitors of Oncogenic Tyrosine Kinases. In: Workman, P., D’lncalci, M. (eds) New Approaches in Cancer Pharmacology: Drug Design and Development. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79088-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79088-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79090-4

  • Online ISBN: 978-3-642-79088-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation